NRX Pharmaceuticals Inc. (NASDAQ: NRXP) and its wholly-owned subsidiary, HOPE Therapeutics, Inc., have announced the signing of a definitive agreement to acquire the Kadima Neuropsychiatry Institute, located in La Jolla, CA. This acquisition is set to form the foundation for the HOPE Network of Interventional Psychiatry Clinics. Kadima, renowned for its pioneering work in CNS and psychedelic research, will serve as the clinical model for HOPE's treatment offerings across the nation. Dr. David Feifel, a distinguished figure in interventional psychiatry, will join HOPE as the Chief Medical Innovation Officer following the acquisition's closure. The transaction, expected to enhance revenue and EBITDA for both NRx and HOPE, is subject to standard closing conditions and finalization of financing. Further details will be disclosed in due course.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。